1-3 of 3
Johan Vansteenkiste
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Risk of Adverse Events Is Similar in Patients (Pts) Who Did or Did Not Achieve Hemoglobin (Hb) Above 12g/dL in a Phase 3 Clinical Trial of Darbepoetin alfa (DA) Administered Weekly (QW) or Every 3 Weeks (Q3W) in Anemic Cancer Pts Receiving Chemotherapy.

Heinz Ludwig, MD, Jean-Luc Canon, MD, Johan Vansteenkiste, MD, PhD, Lisa Hamilton, MSc, Tamás Suto, MD, PhD
Journal: Blood
Blood (2007) 110 (11): 4086.
https://doi.org/10.1182/blood.V110.11.4086.4086
Published: 2007
Journal Articles

Effect of Dose Reductions on Response to 500-μg Darbepoetin alfa Administered Once Every 3 Weeks for the Treatment of Chemotherapy-Induced Anemia: Analysis from a Randomized, Double-Blind, Active-Controlled Trial.

Jean-Luc Canon, MD, Johan Vansteenkiste, MD, Gyorgy Bodoky, MD, Ma Victoria Mateos, MD, Laurent Bastit, MD, Irene Ferreira, PhD, Tom Lillie, MD
Journal: Blood
Blood (2005) 106 (11): 3558.
https://doi.org/10.1182/blood.V106.11.3558.3558
Published: 2005
Journal Articles

Effects of Dose Adjustment Rules on Safety during Erythropoietic Therapy: A Retrospective Analysis of Darbepoetin alfa Administered Either Every 3 Weeks or Weekly.

Michael Hedenus, Jean-Luc Canon, Dusan Kotasek, Tom Lillie, Lisa Hendricks, Bin Yao, Johan Vansteenkiste
Journal: Blood
Blood (2005) 106 (11): 3376.
https://doi.org/10.1182/blood.V106.11.3376.3376
Published: 2005